Open Orphan PLC (LSE: ORPH) has recently extended a contract with a top-three global pharma company. Its Venn Life Services subsidiary, operating out of Breda, Netherlands, will provide chemistry,...
Pharmaceutical services
Open Orphan wins vaccine contract extension and announces toxicology study completion
Open Orphan (LSE: ORPH) subsidiary Venn Life Sciences has extended a consulting contract with a global pharma firm to support two vaccine development programmes. Venn’s Breda office in the...
“We are scaling-up rapidly and at minimum expense” – Open Orphan’s Cathal Friel on the pharma services firm’s exciting plans for 2021 and beyond
Human challenge study pioneer and AIM darling Open Orphan (LSE:ORPH) is set for a record-breaking 2021. The joint London and Dublin-listed pharma services firm is now profitable for the first...
Open Orphan continues to convert deal pipeline with key Venn contracts
Open Orphan’s (LSE:ORPH) strong run continued on Monday morning with the news that it has won two new contracts bolstering its presence in the global fight against coronavirus. The pharmaceutical...
Open Orphan strengthens board with Elaine Sullivan hire
Open Orphan (LSE:ORPH) Tuesday saw pharmaceutical services player Open Orphan (LSE:ORPH) announce the appointment of Elaine Sullivan as a non-executive director to its board. Sullivan is business...
Open Orphan signs £3.2m challenge study deal with upside potential (ORPH)
Friday saw Open Orphan (LSE:ORPH) reveal the signing of a multi-million-pound deal with a European biotech company. The contract, which is projected to deliver £3.2 million in revenue this year,...